Meeting
2022 ASCO Annual Meeting
Favezelimab (anti–LAG-3) plus pembrolizumab in patients with anti–PD-1–naive relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL): An open-label phase 1/2 study.
Authors
Nathalie A. Johnson
Jewish General Hospital, Montréal, QC, Canada
Nathalie A. Johnson , David Lavie , Peter Borchmann , Gareth Gregory , Alex Francisco Herrera , Leonard Minuk , Vladan Vucinic , Philippe Armand , Abraham Avigdor , Robin Gasiorowski , Yair Herishanu , Colm Keane , John Kuruvilla , John Palcza , Pallavi Pillai , Patricia Marinello , John Timmerman
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies
Sub Track
Hodgkin Lymphoma
Clinical Trial Registration Number
NCT03598608
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 7516)
DOI
10.1200/JCO.2022.40.16_suppl.7516
Abstract #
7516
Poster Bd #
170
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Phase 1 trial of the anti-LAG3 antibody favezelimab plus pembrolizumab in advanced gastric cancer.
First Author: Sun Young Rha
Poster
2023 ASCO Annual Meeting
Safety and efficacy of allogeneic natural killer cells in combination with pembrolizumab in patients with chemotherapy-refractory biliary tract cancer: A multicenter open-label phase 1/2a trial.
First Author: Galam Leem
Poster
2023 ASCO Annual Meeting
Final three-year follow-up analysis of phase I/II study on tirabrutinib in patients with relapsed or refractory primary central nervous system lymphoma.
First Author: Katsunori Asai
Poster
2023 ASCO Annual Meeting
The ELiPSE-1 study: A phase 1, multicenter, open-label study of CNTY-101 in subjects with relapsed or refractory CD19-positive B-cell malignancies.
First Author: Krish Patel